Hélène Ribault

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Alberto Bossi, Hélène Ribault, Karim Fizazi · The Lancet · 2024 · 83 citations

Medicine, Radiation Oncology, Urology +13

Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.

Alberto Bossi, Stéphanie Foulon, Xavier Maldonado et al. · Journal of Clinical Oncology · 2023 · 56 citations

Medicine, Oncology, Radiation Oncology +17

Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial.

Helen Jane Boyle, Guilhem Roubaud, S. Supiot et al. · Journal of Clinical Oncology · 2023 · 20 citations

Medicine, Oncology, Urology +17

1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial

X. Maldonado, Guilhem Roubaud, Ray McDermott et al. · Annals of Oncology · 2022 · 12 citations

Medicine, Oncology, Urology +15